期刊
ALZHEIMERS & DEMENTIA
卷 12, 期 9, 页码 1014-1021出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.04.008
关键词
Brain disorders; Alzheimer's dementia; Complexity theory; Systems pharmacology; Systems biology; Drug discovery and development
Massive investment and technological advances in the collection of extensive and longitudinal information on thousands of Alzheimer patients results in large amounts of data. These big-data databases can potentially advance CNS research and drug development. However, although necessary, they are not sufficient, and we posit that they must be matched with analytical methods that go beyond retrospective data-driven associations with various clinical phenotypes. Although these empirically derived associations can generate novel and useful hypotheses, they need to be organically integrated in a quantitative understanding of the pathology that can be actionable for drug discovery and development. We argue that mechanism-based modeling and simulation approaches, where existing domain knowledge is formally integrated using complexity science and quantitative systems pharmacology can be combined with data-driven analytics to generate predictive actionable knowledge for drug discovery programs, target validation, and optimization of clinical development. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据